fbpx

Atara Preclinical Pipeline Expanding with Novel Technology Collaborations

Program
Indication
Target
Technologies
Collaborator
ATA2271
Solid tumors(1)
Mesothelin
PD-1 DNR; Novel 1XX co-stimulation(2)
Memorial Sloan Kettering Cancer Center
ATA2321
AML
Dual-targeted undisclosed
Novel co-stimulation(2)
Moffitt Cancer Center
ATA2431
B-cell malignancies
CD19-CD20-CD22
Novel co-stimulation(2)
Moffitt Cancer Center
ATA3219
B-cell malignancies
CD19
Off-the-shelf, allogeneic; Novel co-stimulation
Atara Bio
Other CAR T Program
Autoimmune disease
Undisclosed
Novel CAR T co-stimulation
Memorial Sloan Kettering Cancer Center
Other CAR T Program
Infectious disease
Undisclosed
Novel CAR T co-stimulation
Memorial Sloan Kettering Cancer Center
ATA621
JCV PML and BKVAN
BK/JCV
Selective viral antigen targeting
ATA368
HPV associated cancers
HPV
Selective viral antigen targeting

AML: acute myeloid leukemia; DNR: Dominant Negative Receptor
(1) Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
(2) Development expected to start in autologous setting

Learn more about Atara’s next generation CAR T technologies and collaborator publications & presentations